Asset Details
Do you wish to reserve the book?
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells
Do you wish to request the book?
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells
2007
Overview
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. However, effective chemopreventive and chemotherapeutic agents for this cancer have not yet been developed. In clinical trials acyclic retinoid (ACR) and vitamin K2 (VK2) decreased the recurrence rate of HCC. In the present study we examined the possible combined effects of ACR or another retinoid 9‐cis retinoic acid (9cRA) plus VK2 in the HuH7 human HCC cell line. We found that the combination of 1.0 µM ACR or 1.0 µM 9cRA plus 10 µM VK2 synergistically inhibited the growth of HuH7 cells without affecting the growth of Hc normal human hepatocytes. The combined treatment with ACR plus VK2 also acted synergistically to induce apoptosis in HuH7 cells. Treatment with VK2 alone inhibited phosphorylation of the retinoid X receptor (RXR)α protein, which is regarded as a critical factor for liver carcinogenesis, through inhibition of Ras activation and extracellular signal‐regulated kinase phosphorylation. Moreover, the inhibition of RXRα phosphorylation by VK2 was enhanced when the cells were cotreated with ACR. The combination of retinoids plus VK2 markedly increased both the retinoic acid receptor responsive element and retinoid X receptor responsive element promoter activities in HuH7 cells. Our results suggest that retinoids (especially ACR) and VK2 cooperatively inhibit activation of the Ras/MAPK signaling pathway, subsequently inhibiting the phosphorylation of RXRα and the growth of HCC cells. This combination might therefore be effective for the chemoprevention and chemotherapy of HCC. (Cancer Sci 2007; 98: 431–437)
Publisher
Blackwell Publishing Asia,Blackwell
Subject
Antineoplastic Agents - pharmacology
/ Biological and medical sciences
/ Carcinoma, Hepatocellular - drug therapy
/ Carcinoma, Hepatocellular - metabolism
/ Carcinoma, Hepatocellular - pathology
/ Dose-Response Relationship, Drug
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Liver Neoplasms - drug therapy
/ Liver Neoplasms - metabolism
/ Liver. Biliary tract. Portal circulation. Exocrine pancreas
/ Original
/ Tretinoin - analogs & derivatives
/ Tumors
